The end of the month in April, this year, it applied for the fellowship grant of the 21st century type medical exploitation promotion research enterprise which the Ministry of Health, Labour and Welfare sponsors. I will hear that it probably does not come out of a subsidy to our research that a reply does not come at this time. Moreover, a self-belly must be cut with the fund of a company and research must be continued. (The president, I am sorry.)
By the way, I introduce about the contents of research for which it applied when it applied for this subsidy. The title of research is "research of the prevention and the relief about Alzheimer's disease."
It is suggested that KARUPAIN which is a kind of protein decomposition enzyme is participating in development of symptoms of Alzheimer's disease. A possibility that protein called p25 related to development of symptoms of Alzheimer's disease by the group of Harvard University toward the twilight was reported the year before last. Although the protein called p35 exists in the nerve cell within a normal brain, they say that p35 changes to p25 and this causes nerve cell death in the nerve cell within the brain of Alzheimer's disease. It became clear in June last year that the enzyme changed to p25 from p35 is protein decomposition enzyme called KARUPAIN. When p35 could prevent nerve cell death as it did not change to p25 while controlling superfluous production of KARUPAIN so that protein might not be made to disassemble if it was it, I thought that Alzheimer's disease was also solvable.
As for man, the functional fall of the body starts with a peak of the time of 20 years old. The capability to produce the enzyme which was functioning normally also declines with age at the time of 20 years old. Composition of energy source ATP (adenosine 3 Lynn acid) common to a living thing is activated by KIPPO, and it is thought that what is necessary is normalizing the productive capacity of enzyme, stabilizing protein and making it just not make it decompose by the energy. Moreover, although it is said that the "oxygen radical" is concerned with development of symptoms of Alzheimer, in KIPPO, "the removal stability of an oxygen radical" more powerful than what food is possible. Alzheimer is solution in normalization of enzyme production, and the removal stability of an oxygen radical.
From here, it is my individual grumble.
The subsidy is paid for research of each ministry agency and a foundation of biotechnology, IT, or others. However, if the actual result of past research subject adoption is seen, as for the investment place, the university of a national system and a research organization are hardly contributed for the so-called private company by most. Although it seems that IT relation finances a venture business in many cases rather than biotechnology, there is inconsistency also in that case. For example, when it applies for a subsidy in April and a subject is adopted around June, a research cost will be paid in September. However, it is not paid if there will be no 25 million yen receipt among the research costs of 50 million yen by September. Although there will be no problem of funds if it is the company and research organization of a major company, for a venture business, it is a life-and-death problem, and since funds is not furnished unless a bank has an actual result although it applies for a loan to a bank confusedly, the fact that a subsidy cannot receive has occurred. It is a very strange system! Now, can't Japan do in a venture business etc.? It seems to be better to move the base of activity. It seems that in fact, the Munich university in Germany, the specialist of the cancer of Canada, etc. are interested in this research.
Of course, a research direct flight (direct-delivery-from-the-farm ?) does not change KIPPO from overseas. The purchase by Japan is a "Yagi pharmacy"!!